Merck & Co., Inc. (6MK.F)
| Previous Close | 120.80 |
| Open | 121.20 |
| Bid | 120.20 x 100000 |
| Ask | 121.20 x 100000 |
| Day's Range | 121.20 - 121.40 |
| 52 Week Range | 90.70 - 123.20 |
| Volume | |
| Avg. Volume | 349 |
| Market Cap | 308.464B |
| Beta (5Y Monthly) | 0.40 |
| PE Ratio (TTM) | 146.27 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 2.84 (2.35%) |
| Ex-Dividend Date | Mar 14, 2024 |
| 1y Target Est | N/A |
- CNW Group
Health Canada Approves KEYTRUDA® for adult patients with locally advanced unresectable or metastatic biliary tract carcinoma, in combination with gemcitabine-based chemotherapy
Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced that Health Canada has granted approval of KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, in combination with gemcitabine-based chemotherapy, for the treatment of adult patients with locally advanced unresectable or metastatic biliary tract carcinoma (BTC). This approval is based on the results from the Phase 3 KEYNOTE-966 trial, which demonstrated a statistically significant and clinically meaningful improvem
- Business Wire
Merck Provides Update on Phase 3 KEYNOTE-B21 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Chemotherapy, With or Without Radiotherapy, for Patients With Newly Diagnosed, High-Risk Endometrial Cancer After Surgery With Curative Intent
RAHWAY, N.J., May 09, 2024--Merck Provides Update on Phase 3 KEYNOTE-B21 Trial
- ACCESSWIRE
Merck Expands Access to High-Quality Maternal Care for More Than 30 Million Women Worldwide Through Merck for Mothers
Surpasses its goal of reaching 25 million women by 2025 RAHWAY, NJ / ACCESSWIRE / May 8, 2024 / Merck (NYSE:MRK), known as MSD outside of the United States and Canada, announced today that Merck for Mothers, the company's global maternal health initiative, ...
